Statistical methods for building better biomarkers of chronic kidney disease

The last two decades have witnessed an explosion in research focused on the development and assessment of novel biomarkers for improved prognosis of diseases. As a result, best practice standards guiding biomarker research have undergone extensive development. Currently, there is great interest in the promise of biomarkers to enhance research efforts and clinical practice in the setting of chronic kidney disease, acute kidney injury, and glomerular disease. However, some have questioned whether biomarkers currently add value to the clinical practice of nephrology. The current state of the art pertaining to statistical analyses regarding the use of such measures is critical.

• Publication year

  2019

• Venue

  Statistics in Medicine

• Publication date

  2019-01-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/sim.8091PMID 30663113
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Longitudinal Data Analysis

  2020cited by this paper
• Adversarial Time-to-Event Modeling

  2018cited by this paper
• A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density

  2016cited by this paper
• The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men. Vedder,

  2016cited by this paper
• Supporting open access to clinical trial data for researchers: The Duke Clinical Research Institute-Bristol-Myers Squibb Supporting Open Access to Researchers Initiative.

  2016cited by this paper
• Tests of calibration and goodness‐of‐fit in the survival setting

  2015cited by this paper
• Merging multiple longitudinal studies with study‐specific missing covariates: A joint estimating function approach

  2015cited by this paper
• Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration

  2015cited by this paper
• Limitations in the conventional assessment of the incremental value of predictors of cardiovascular risk.

  2015cited by this paper
• Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease

  2015cited by this paper
• External validation of new risk prediction models is infrequent and reveals worse prognostic discrimination.

  2015cited by this paper
• Calibration of Risk Prediction Models

  2015cited by this paper
• Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement

  2015cited by this paper
• Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement

  2015cited by this paper
• The Role of Physicians in the Era of Predictive Analytics.

  2015cited by this paper
• Sharing clinical trial data: maximizing benefits, minimizing risk.

  2015cited by this paper
• The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

  2014cited by this paper
• Covariate-adjusted measures of discrimination for survival data

  2014cited by this paper
• Key concepts and limitations of statistical methods for evaluating biomarkers of kidney disease.

  2014cited by this paper
• Developing risk prediction models for kidney injury and assessing incremental value for novel biomarkers.

  2014cited by this paper
• Does the Net Reclassification Improvement Help Us Evaluate Models and Markers?

  2014cited by this paper
• F1000Prime recommendation of Calibration of risk prediction models: impact on decision-analytic performance.

  2014cited by this paper
• Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives

  2014cited by this paper
• Methods for dealing with time‐dependent confounding

  2013cited by this paper
• Testing for improvement in prediction model performance

  2013cited by this paper
• When does combining markers improve classification performance and what are implications for practice?

  2013cited by this paper
• Impact of correlation on predictive ability of biomarkers

  2013cited by this paper
• Multicategory reclassification statistics for assessing improvements in diagnostic accuracy.

  2013cited by this paper
• Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility.

  2013cited by this paper
• Clustering for multivariate continuous and discrete longitudinal data

  2013cited by this paper
• Experimental designs for identifying causal mechanisms

  2013cited by this paper
• Evaluation of Markers and Risk Prediction Models

  2013cited by this paper
• Misuse of DeLong test to compare AUCs for nested models

  2012cited by this paper
• Biases introduced by choosing controls to match risk factors of cases in biomarker research.

  2012cited by this paper
• Quadratic inference function approach to merging longitudinal studies: validation and joint estimation

  2012cited by this paper
• Thoroughly Modern Risk Prediction?

  2012cited by this paper
• Clinically relevant graphical predictions from Bayesian joint longitudinal-survival models

  2012cited by this paper
• Interpreting incremental value of markers added to risk prediction models.

  2012cited by this paper
• Extending the c‐statistic to nominal polytomous outcomes: the Polytomous Discrimination Index

  2012cited by this paper
• Age and association of kidney measures with mortality and end-stage renal disease.

  2012cited by this paper
• Evaluating the incremental value of new biomarkers with integrated discrimination improvement.

  2011cited by this paper
• [Regression modeling strategies].

  2011cited by this paper
• Practice of Epidemiology Problems With Risk Reclassification Methods for Evaluating Prediction Models

  2011cited by this paper
• An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

  2011cited by this paper
• Assessing the incremental value of diagnostic and prognostic markers: a review and illustration

  2011cited by this paper
• Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study

  2011cited by this paper
• A model for dissemination and independent analysis of industry data.

  2011cited by this paper
• Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures

  2010cited by this paper
• External validity of risk models: Use of benchmark values to disentangle a case-mix effect from incorrect coefficients.

  2010cited by this paper
• JM: An R package for the joint modelling of longitudinal and time-to-event data

  2010cited by this paper
• Basic concepts and methods for joint models of longitudinal and survival data.

  2010cited by this paper
• Using relative utility curves to evaluate risk prediction

  2009cited by this paper
• Prognostic Models With Competing Risks: Methods and Application to Coronary Risk Prediction

  2009cited by this paper
• Measuring classifier performance: a coherent alternative to the area under the ROC curve

  2009cited by this paper
• Criteria for Evaluation of Novel Markers of Cardiovascular Risk: A Scientific Statement From the American Heart Association

  2009cited by this paper
• Coefficients of Determination in Logistic Regression Models—A New Proposal: The Coefficient of Discrimination

  2009cited by this paper
• Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.

  2008cited by this paper
• Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond

  2008cited by this paper
• Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction

  2007cited by this paper
• Hemoglobin variability and mortality in ESRD.

  2007cited by this paper
• Multiple biomarkers for the prediction of first major cardiovascular events and death.

  2006cited by this paper
• Guidance for Industry and FDA Staff

  2006cited by this paper
• Endogenous Sex Hormones and Cardiovascular Disease Incidence in Men

  2006cited by this paper
• Estimation of time‐dependent area under the ROC curve for long‐term risk prediction

  2006cited by this paper
• Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors

  2005cited by this paper
• Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation

  2004cited by this paper
• Internal validation of predictive models: efficiency of some procedures for logistic regression analysis.

  2001cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• Statistical Models Based on Counting Processes.

  1996cited by this paper
• The Area under the ROC Curve and Its Competitors

  1991cited by this paper
• Measures of explained variation for survival data.

  1990cited by this paper
• Causal Inference, Path Analysis and Recursive Structural Equations Models. Program Statistics Research, Technical Report No. 88-81.

  1988cited by this paper
• Structural Equations and Path Analysis for Discrete Data

  1983cited by this paper
• External correspondence: Decompositions of the mean probability score

  1982cited by this paper

• Design aspects for prognostic factor studies

  2025cites this paper
• Toward practical implementation of predictive models: cost-effective thresholds in machine learning models for chronic kidney disease screening

  2025cites this paper
• Communicating health risk in chronic kidney disease: a scoping review

  2024cites this paper
• Impact of Chronic Kidney Disease on the Associations of Cardiovascular Biomarkers With Adverse Outcomes in Patients With Suspected or Known Coronary Artery Disease: The EXCEED‐J Study

  2022cites this paper
• Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease

  2022cites this paper
• Multi-cohort and longitudinal Bayesian clustering study of stage and subtype in Alzheimer’s disease

  2022cites this paper
• Toward Personalized Radiation Therapy of Liver Metastasis: Importance of Serial Blood Biomarkers.

  2021cites this paper
• Urine Metabolite Levels, Adverse Kidney Outcomes, and Mortality in CKD Patients: A Metabolome-wide Association Study.

  2021cites this paper
• Constructing a Model with Binary Response to Some of the Factors Affecting the Incidence of Chronic Kidney Failure

  2021cites this paper
• Metabolomic Markers of Kidney Function Decline in Patients With Diabetes: Evidence From the Chronic Renal Insufficiency Cohort (CRIC) Study.

  2020cites this paper
• Contribution of Predictive and Prognostic Biomarkers to Clinical Research on Chronic Kidney Disease

  2020cites this paper
• Acute kidney injury biomarkers in the critically ill.

  2020cites this paper